Liver transplantation for chronic hepatitis C – the importance of antiviral therapy in 2024

Czech version

Authors: S. Fraňková; V. Pítová; J. Šperl
Authors‘ workplace: Klinika hepatogastroenterologie, Transplantcentrum, Institut klinické a experimentální medicíny, Praha
Published in: Gastroent Hepatol 2024; 78(2): 108-114
Category: Hepatology
doi: https://doi.org/10.48095/ccgh2024108

Overview

Liver failure due to cirrhosis and hepatocellular carcinoma (HCC) in hepatitis C (HCV) infection is still one of the main indications for liver transplantation (LTx) in Western countries. In patients with compensated liver cirrhosis C, antiviral therapy should be initiated promptly, as complications, i.e. decompensation of the disease and HCC, can occur in a short time frame. Successful antiviral treatment of HCV in patients with cirrhosis reduces the risk of decompensation, HCC, and death from liver failure, thus reducing the need for LTx in these patients. Treatment in a patient with decompensated liver cirrhosis before LTx aims not only to prevent HCV recurrence in the liver graft but also to improve liver function. In patients on the waiting list, improvement of liver function may lead to removal from the waiting list. LTx should be considered in all patients with chronic liver failure due to HCV in whom we expect prolongation of life expectancy after LTx compared to the natural course of their liver disease or for whom LTx will significantly improve the quality of life. LTx should be considered when life expectancy due to liver disease is one year or less. Before LTx, the patient should be thoroughly examined to exclude comorbidities that substantially complicate or preclude LTx. The advent of direct-acting antivirals into HCV treatment regimens represents a revolutionary step to prevent HCV recurrence in the graft, is either by eradicating HCV before LTx or by early treatment after LTx. Currently, HCV recurrence in the liver graft either by eradicating HCV before LTx or by early treatment after LTx. Currently, HCV recurrence in the liver graft no longer leads to worse survival in patients transplanted for HCV, and outcomes are fully comparable to those of LTx for other diagnoses.

Keywords:

HCV – cirrhosis C – liver failure – hepatocellular carcinoma – liver transplantation – HCV recurrence

Sources

1. Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol 2022; 7 (5): 396–415. doi: 10.1016/S2468-1253 (21) 00472-6.

2. Chlibek R, Smetana J, Sosovickova R et al. Prevalence of hepatitis C virus in adult population in the Czech Republic – time for birth cohort screening. PLoS One 2017; 12 (4): e0175525. doi: 10.1371/journal.pone.0175525.

3. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36 (5 Suppl 1): S47–S56. doi: 10.1053/jhep.2002.36993.

4. Saeed H, Cano EJ, Khan MQ et al. Changing landscape of liver transplantation in the post-DAA and contemporary ART era. Life (Basel) 2022; 12 (11): 1755. doi: 10.3390/life12111755.

5. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol 2020; 73 (5): 1170–1218. doi: 10.1016/ j.jhep.2020.08.018.

6. Pawlotsky JM. The science of direct-acting antiviral and host-targeted agent therapy. Antivir Ther 2012; 17 (6 Pt B): 1109–1117. doi: 10.3851/IMP2423.

7. Poynard T, Colombo M, Bruix J et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136 (5): 1618.e2– –1628.e2. doi: 10.1053/j.gastro.2009.01.039.

8. Negro F. Residual risk of liver disease after hepatitis C virus eradication. J Hepatol 2021; 74 (4): 952–963. doi: 10.1016/j.jhep.2020.11.040.

9. Belli LS, Duvoux C, Berenguer M et al. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. J Hepatol 2017; 67 (3): 585–602. doi: 10.1016/ j.jhep.2017.03.006.

10. Belli LS, Berenguer M, Cortesi PA et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol 2016; 65 (3): 524–531. doi: 10.1016/j.jhep.2016.05.010.

11. Terrault NA, Zeuzem S, Di Bisceglie AM et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology 2016; 151 (6): 1131.e5–1140.e5. doi: 10.1053/j.gastro.2016.08. 004.

12. Foster GR, Irving WL, Cheung MC et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016; 64 (6): 1224–1231. doi: 10.1016/j.jhep.2016.01.029.

13. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: liver transplantation. J Hepatol 2016; 64 (2): 433–485. doi: 10.1016/j.jhep.2015.10.006.

14. Ioannou GN, Splan MF, Weiss NS et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007; 5 (8): 938–945. doi: 10.1016/j.cgh.2007.02.039.

15. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11): 693–699. doi: 10.1056/NEJM199603143341104.

16. van der Meer AJ, Veldt BJ, Feld JJ et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308 (24): 2584–2593. doi: 10.1001/jama.2012.144878.

17. Berenguer M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl 2003; 9 (11): S44–S47. doi: 10.1053/jlts.2003.50243.

18. Sperl J, Frankova S, Trunecka P. Transplantace jater pro chronickou hepatitidu C, význam protivirové léčby. Gastroent Hepatol 2013; 67 (5): 407–412.

19. Neumann UP, Berg T, Bahra M et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41 (5): 830–836. doi: 10.1016/j.jhep.2004.06.029.

20. Forman LM, Lewis JD, Berlin JA et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122 (4): 889–896. doi: 10.1053/gast.2002.32418.

21. Schluger LK, Sheiner PA, Thung SN et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23 (5): 971–976. doi: 10.1002/hep.5102 30505.

22. Dixon LR, Crawford JM. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl 2007; 13 (2): 219–226. doi: 10.1002/lt.21011.

23. Agarwal K, Castells L, Mullhaupt B et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1–4 HCV-infected liver transplant recipients. J Hepatol 2018; 69 (3): 603–607. doi: 10.1016/ j.jhep.2018.05.039.

24. Reau N, Kwo PY, Rhee S et al. Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection. Hepatology 2018; 68 (4): 1298–1307. doi: 10.1002/hep.30046.

ORCID autorů

S. Fraňková 0000-0002-1462-5920,

J. Šperl 0000-0001-8619-2610.

Doručeno/Submitted: 18. 3. 2024

Přijato/Accepted: 25. 3. 2024

MUDr. Soňa Fraňková, Ph.D.

Klinika hepatogastroenterologie

Institut klinické a experimentální medicíny

Vídeňská 1958/9

140 21 Praha 4

sona.frankova@ikem.cz